| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000027127 |
| Receipt No. | R000031084 |
| Scientific Title | Investigation of availability of chemical shift MRI in a nodule shadow doubting pulmonary hamartoma or benign pulmonary tumor in chest CT |
| Date of disclosure of the study information | 2017/04/25 |
| Last modified on | 2022/11/09 (Ver. 10) |
| Basic information | ||
| Public title | Investigation of availability of chemical shift MRI in a nodule shadow doubting pulmonary hamartoma or benign pulmonary tumor in chest CT | |
| Acronym | LOGIK1701 | |
| Scientific Title | Investigation of availability of chemical shift MRI in a nodule shadow doubting pulmonary hamartoma or benign pulmonary tumor in chest CT | |
| Scientific Title:Acronym | LOGIK1701 | |
| Region |
|
|
| Condition | |||
| Condition | Pulmonary hamartoma | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | We prospectively collect the clinical information that chemical shift MRI was carried out in patients doubting pulmonary hamartoma or pulmonary benign tumor in chest CT in multicenter study and investigate availability of chemical shift MRI for preoperative diagnosis of pulmonary hamartoma by comparing with pathology findings after resection. |
| Basic objectives2 | Others |
| Basic objectives -Others | Sensitivity and specificity of pulmonary hamartoma diagnosis by chemical shift MRI |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Sensitivity and specificity of pulmonary hamartoma diagnosis by chemical shift MRI |
| Key secondary outcomes | Positive predictive value in the range of virtual prevalence, ratio of each operative method (enucleation, wedge resection, segmental resection, lobectomy and others), exploration of cut-off value of signal intensity index. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Chemical shift MRI is carried out in patients who pulmonary hamartoma or benign pulmonary tumor was suspected in chest CT and it is compared between the pathological results after tumor resection and the findings of chemical shift MRI | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients providing the written informed consent. (legal representatives are included in the case of a minor subjects)
2) Patients in whom diagnosis of lung cancer is not confirmed and pulmonary hamartoma or benign pulmonary tumor was doubted in chest CT. In addition, patients with bronchial intervention for bronchial hamartoma are eligible. 3) Patients with 10 mm or more of nodal shadow in minor axis by CT. 4) Patients who agree to enforcement of chemical shift MRI within 3 months after enrollment. 5) Patients who agree to tumor resection within 6 months after chemical shift MRI enforcement. 6) Age >= 18 years of age at the time of enrollment. 7) PS 0 or 1. |
|||
| Key exclusion criteria | 1) Patients with apparent complication of suspicious primary or metastatic pulmonary tumors from imaging diagnosis and progress.
2) Patients with metastatic pulmonary tumor as primary lesion of 1:renal cell carcinoma, 2:hepatic cell carcinoma and 3:liposarcoma (because fat component is included in tumor) and without passed 5 year after occurrence of primary lesion. 3) Any other patients who are regarded as unsuitable for the study by the investigators. 4) Patients who can't medically and mentally have MRI examination 5) Patients who refuse the participation in the study |
|||
| Target sample size | 290 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kagoshima University Hospital | ||||||
| Division name | Department of Thoracic Surgery | ||||||
| Zip code | 890-8520 | ||||||
| Address | 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan | ||||||
| TEL | 099-275-6490 | ||||||
| m-sato@m2.kufm.kagoshima-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kagoshima University Hospital | ||||||
| Division name | Department of Operation | ||||||
| Zip code | 890-8520 | ||||||
| Address | 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan | ||||||
| TEL | 099-275-6490 | ||||||
| Homepage URL | |||||||
| k6474547@kadai.jp | |||||||
| Sponsor | |
| Institute | Clinical Research Support Center Kyushu |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Clinical Research Support Center Kyushu |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | kagoshima University Hospital institutional review board |
| Address | 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan |
| Tel | 099-275-6692 |
| kyufsyomu@kuas.kagoshima-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 109 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000031084 |